Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Stein, Anthony
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
I
Nakamura R
,
Gendzekhadze K
,
Palmer J
,
Tsai N-C
,
Mokhtari S
,
Forman SJ
,
Zaia JA
,
Senitzer D
,
Marcucci G
,
Stein A
.
Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
Leuk Res. 2019;87:106230.
PubMed
Google Scholar
L
Khaldoyanidi SK
,
Hindoyan A
,
Stein A
,
Subklewe M
.
Leukemic Stem Cells as a Target for Eliminating Acute Myeloid Leukemia: Gaps in Translational Research.
Crit Rev Oncol Hematol. 2022:103710.
PubMed
Google Scholar
P
Ladbury C
,
Sanchez J
,
Chowdhury A
,
Palmer J
,
Liu A
,
Stein A
,
Htut M
,
Farol L
,
Cai J-L
,
Somlo G
, et al.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Am J Clin Oncol. 2024.
PubMed
Google Scholar
R
Mei M
,
Palmer J
,
Tsai NNi-Chun
,
Simpson J
,
O'Hearn J
,
Stein A
,
Forman S
,
Spielberger R
,
Cai J-L
,
Htut M
, et al.
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Clin Lymphoma Myeloma Leuk. 2023.
PubMed
Google Scholar
Ladbury C
,
Armenian S
,
Bosworth A
,
He T
,
F Wong L
,
Dandapani S
,
Han C
,
Liu A
,
Malki MAl
,
Rosenthal J
, et al.
Risk of subsequent malignant neoplasms following hematopoietic stem cell transplantation with total body irradiation or total marrow irradiation: insights from early follow-up.
Transplant Cell Ther. 2022.
PubMed
Google Scholar